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Abstract
Background Personal treatment goals have been systematically investigated in psoriasis patients with active but not in 
controlled disease.
Objectives To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, 
etanercept or ustekinumab.
Methods Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 
months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire 
(PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be 
quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 
years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy.
Results Sixty-five patients were included. ‘To be free of itching’, ‘to be healed of all skin defects’ and ‘to have confidence 
in the therapy’ were rated quite/very important in 78.5% of the patients, followed by ‘to have no fear the disease will pro-
gress’ (75.4%) and ‘to get better skin quickly’ (75.4%). Goals related to the subscale ‘confidence in healing’ were still of 
high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was 
significantly more important than for males to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’.
Conclusions Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed 
to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level.
Plain Language Summary
In psoriasis patients, a large reduction in disease severity can lead to a significant improvement in health-related quality of 
life. In addition to quality-of-life measurements, individual treatment goals can be assessed to evaluate patients’ preferences 
regarding their psoriasis treatment. As opposed to patients with more severe psoriasis, unmet treatment needs in psoriasis 
patients with stable, low disease activity have barely been reported. In this study, the personal treatment aims of patients 
with controlled disease due to treatment with adalimumab, etanercept or ustekinumab were explored using the Patient Needs 
Questionnaire. Sixty-five patients with sustained low disease activity for ≥ 6 months were included. We found that despite 
low disease activity, these patients still have substantial patient needs. Patients attributed the highest importance to goals 
on confidence in healing, in contrast to social goals, which were valued of least importance. For female patients, it was sig-
nificantly more important to ‘feel less depressed’ and ‘be comfortable showing yourself more in public’ compared to male 
patients. Previous treatment with biologic therapy was not associated with an altered attitude towards specific treatment goals. 
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Our population with low disease activity seemed to award a lower level of importance to all treatment goals compared to 
groups of patients with more severe psoriasis that have been described in literature. Since treatment goals differ per patient, 
individual treatment could be optimized by actively inquiring about the patient’s personal treatment goals. Clinicians should 
be aware that even in patients with controlled disease, substantial personal treatment needs remain.
Key Points 
Despite low disease activity, psoriasis patients with 
controlled disease due to biologic treatment still have 
substantial treatment goals.
In this cohort of psoriasis patients with low disease 
activity, goals related to ‘confidence in healing’ were 
considered most important. Social goals were of least 
importance.
1 Introduction
Psoriasis is an immune-mediated chronic inflammatory skin 
disease that has a significant impact on the patient’s qual-
ity of life (QoL) [1]. For both dermatologists and patients, 
reducing the severity of the disease is the main goal of pso-
riasis treatment [2]. Over the past few years, various targeted 
biological therapies have become available, enabling a Pso-
riasis Area of Severity Index (PASI) reduction of > 75%, or 
even complete remission [3, 4].
It has been reported that a large reduction in the PASI 
score as a result of biologic therapy can lead to a significant 
improvement in QoL [5]. However, in a study on 1-year drug 
survival of adalimumab, etanercept and ustekinumab, we 
found that 21% of the patients still reported a Dermatology 
Life Quality Index (DLQI) > 5 (a moderate or even larger 
effect on the QoL) after 1 year of biologic treatment [6]. 
These results indicate that even when patients are in (partial) 
remission, treatment goals may still continue to exist in this 
chronic disease. To focus even more on individual patient 
needs, in addition to QoL, personal treatment goals can be 
assessed.
In patients with moderate to severe psoriasis and/or nail 
psoriasis, a wide range of personal treatment goals have 
already been explored by using the Patient Needs Ques-
tionnaire (PNQ) as part of the Patient Benefit Index (PBI) 
[7–10]. Patient needs in psoriasis patients with sustained 
controlled disease activity, on the other hand, have rarely 
been studied. It is important to get insight into the indi-
vidual treatment goals of this population in order to opti-
mize treatment, improve treatment adherence and facilitate 
personalized medicine. In the current era, with an expanding 
arsenal of biologic therapies with the potential to achieve a 
significant reduction of disease severity, this will become 
increasingly relevant.
In this study, by means of the PNQ, we investigated the 
personal treatment aims of psoriasis patients with controlled 
disease who were using adalimumab, etanercept or usteki-
numab in order to get insight into the unmet treatment needs 
in this population. To date, this has been an under-reported 
area in psoriasis research.
2  Materials and Methods
2.1  Data Collection and Extraction
From 22 February 2018, over a time-frame of 1 year, all 
adult psoriasis patients who were treated with biologics 
in the Department of Dermatology, Radboud University 
Medical Centre (Radboudumc), Nijmegen, the Netherlands 
were screened for a pragmatic dose-reduction strategy in 
patients with low, stable disease activity on the authorized 
standard dose of the biologics adalimumab, etanercept or 
ustekinumab, and invited to participate if eligible. Stable, 
low disease activity (controlled disease) was defined as low 
disease activity for at least 6 months according to the treat-
ing physician, and preferably a PASI score ≤ 5 at inclu-
sion. Oral consent was obtained prior to participation. At 
the start of the dose reduction strategy (baseline), the PNQ 
was conducted. In addition, PASI scores were determined, 
and Dermatology Life Quality Index (DLQI) questionnaires 
were completed by the patients to measure the effect of pso-
riasis on the health-related quality of life. Patient character-
istics were extracted from the prospective BioCAPTURE 
registry [11, 12], and included gender, age, age at psoriasis 
onset, body mass index (BMI), co-medication, presence of 
psoriatic arthritis, previous PASI scores and history of use 
of a biologic drug. Additionally, the duration of stable dis-
ease was calculated as the time the patient had a PASI ≤ 5 
in regular clinic visits prior to the baseline visit. Patients 
on adalimumab, etanercept or ustekinumab who were eligi-
ble for, but refrained from, inclusion in the dose-reduction 
strategy could volunteer to fill out the PNQ. Since this dose-
reduction strategy was implemented as part of daily practice, 
data on patients who denied dose reduction were collected 
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anonymously, to ensure these patients that refraining from 
dose reduction would not influence their psoriasis treatment.
2.2  Patient Needs Questionnaire
Treatment needs were explored at baseline using the PNQ 
[10]. The PNQ validated for psoriasis consists of 25 therapy 
goals, to which the patients allocate a score ranging from 0 
(not important at all) to 4 (very important). As an alterna-
tive, ‘does not apply to me’ is an option, which was valued 
as a score of 0 in the analyses [13]. Twenty-three out of 25 
therapy goals can be assigned to five distinguishable sub-
scales: reducing psychological impairments, reducing social 
impairments, reducing impairments due to therapy, reducing 
physical impairments, and building confidence into therapy. 
Treatment aims ‘to get better skin quickly’ and ‘to regain 
control of the disease’ are not allocated to any subscale [14].
2.3  Statistical Analysis
Patient and treatment baseline characteristics were collected 
and analysed. Goal importance was calculated both as the 
mean PNQ score per item and the percentage of patients rat-
ing a goal ‘quite’ or ‘very’ important (=PNQ score 3 or 4). 
In case of missing PNQ data, importance scores were calcu-
lated over the available data. Patient needs were analysed as 
per biologic, PNQ subscale, gender, age group (< 50 years 
vs. ≥ 50 years), and biologic treatment history. Additionally, 
anonymous PNQ data on patients who denied dose reduction 
were compared to the PNQ data of our study population. 
Data were analysed using descriptive statistics and standard 
parameters. In comparing continuous outcomes, independ-
ent T-tests were performed for parametric variables and 
Mann–Whitney U tests were performed for non-parametric 
variables. The threshold of statistical significance was set at 
p < 0.05. All statistical analyses were performed using SPSS 
(Version 25.0, IBM Corp., Armonk, NY, USA).
3  Results
Out of 305 patients on biologic therapy who were screened 
to participate in the dose-reduction strategy, 101 were eligi-
ble according to the inclusion criteria. A total of 204 patients 
were ineligible for dose reduction, due to, for example, 
uncontrolled disease, the use of biologic agents other than 
adalimumab, etanercept and ustekinumab, or only recent 
introduction of the biologics of interest (< 6 months ago). 
Sixty-eight patients out of 101 started dose-tapering, of 
whom three patients did not complete the PNQ, leaving 65 
patients with a stable, low disease activity who completed 
the PNQ as the main patient group of focus in this study. 
Out of all eligible patients, 33 decided not to be included 
for the dose-reduction project, of whom 28 completed the 
PNQ anonymously. Baseline characteristics of the dose-
tapering cohort are presented in Table 1. The median PASI 
score and DLQI were 1.6 and 0.0, respectively, indicating 
low disease activity and no effect of psoriasis on quality of 
life. Except for one patient with an absolute PASI score of 
6, all patients had a PASI score ≤ 5. At inclusion, PASI75 
had been reached by 44 patients (71%). The median stable 
disease duration was 2.64 years. The majority of patients 
were male (68%). Most patients used adalimumab (55%), 
followed by ustekinumab (26%) and etanercept (19%). The 
median BMI was 24.7 kg/m2. Fourteen patients (22%) had 
concomitant psoriatic arthritis.
3.1  Overall Goal Importance
Patient needs that were rated most important were ‘to get 
better skin quickly’ (mean PNQ score 3.11, 95% confidence 
interval (CI) 2.75–3.46), ‘to be free of itching’ (mean PNQ 
score 3.09, 95% CI 2.71–3.47) and ‘to be healed of all skin 
defects’ (mean PNQ score 3.09, 95% CI 2.75–3.44). Of least 
importance were ‘to have fewer out-of-pocket-expenses’ 
(mean PNQ score 1.57, 95% CI 1.14–2.00), ‘to be less of a 
burden to relatives and friends’ (mean PNQ score 1.66, 95% 
CI 1.24–2.08) and ‘to be able to lead a normal working life’ 
(mean PNQ score 1.75, 95% CI 1.31–2.20) (Fig. 1). The 
option ‘did/does not apply to me’ was most often chosen for 
‘to be able to lead a normal working life’ (36.9%), ‘to be able 
to sleep better’ (33.8%) and ‘to have fewer out-of-pocket 
treatment costs’ (30.8%). Only seven patients reported ‘to 
have no fear that the disease will progress’ or ‘to be healed 
of all skin defects’ was not applicable, or not important to 
them.
When goal importance was expressed as the percentage 
of patients that rated the goal to be quite/very important 
(PNQ score 3 or 4), ‘to be free of itching’, ‘to be healed of 
all skin defects’ and ‘to have confidence in the therapy’ were 
of high importance in 78.5% of the patients, followed by ‘to 
have no fear the disease will progress’ (75.4%), ‘to get better 
skin quickly’ (75.4%) and ‘to regain control of the disease’ 
(72.3%) (Fig. 2).
The ranking of PNQ items slightly varied when they were 
ranked by mean importance score rather than the percent of 
patients that scored a 3 or a 4 for each item. However, the 
variation in relative rank order did not exceed three places, 
taking similar ranks as a consequence of identical mean 
importance scores or the percentage scored as quite/very 
important into account (Figs. 1 and 2).
Of the five PNQ subscales, most importance was assigned 
to ‘building confidence into therapy’ (mean PNQ subscale 
score 2.85 ± 1.26). ‘Reducing social impairments’ was of 
least importance (mean PNQ subscale score 1.97 ± 1.36) 
(Fig. 3).
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Differences in treatment goals by type of biologic are 
shown in Figs. 1 and 2 and described in Online Supplemen-
tary Material (OSM) 2.
3.2  Personal Treatment Goals by Gender
Analysed by gender, there were no statistically signifi-
cant differences in treatment goals, except for ‘to feel less 
depressed’ (mean PNQ score 2.43 vs. 1.57, p = 0.05) and 
‘to be comfortable showing yourself more in public’ (mean 
PNQ score 3.10 vs. 2.11, p = 0.02), which were rated sig-
nificantly higher in female patients. Overall, female patients 
attributed higher scores to all treatment goals than men, 
except for ‘to be able to lead a normal sex life’, ‘be free 
of pain’, ‘need less time for daily treatment’ and ‘be less 
dependent on doctor and clinic visits’ (Fig. 4).
3.3  Personal Treatment Goals by Age
The younger patients (< 50 years old) assigned higher 
importance scores to 23 out of the 25 PNQ items. The mean 
importance scores attributed to ‘to be able to lead a normal 
everyday life’, ‘to be comfortable showing yourself more in 
public’, ‘to regain control of the disease’, ‘to have fewer side 
effects’ and ‘to be able to lead a normal working life’ proved 
significantly higher in the younger patient group (Fig. 5).
Table 1  Patient characteristics
DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity index
a 10 missing values
b Two missing values
c One missing value
d Three missing values
Characteristics N (%) Median (range) Mean ± SD
Patient characteristics
Gender (male) 44 (68%)
Age (years) 55 (22–79)
Age at psoriasis onset (years) 23 (3–59)
Psoriatic disease duration (years) 26 (6–59)
Body mass index (kg/m2)a 24.7 (17.07–38.24)
Psoriatic arthritis 14 (22%)
Disease activity
PASI at start of current  biologicb 10.2 (2.1–27.4)
PASI at start dose-reduction  strategyc 1.6 (0.0–6.0)
DLQI at start dose-reduction strategy 0.0 (0.0–18.0)
Mean duration of stable disease (PASI ≤ 5) at baseline (years) 3.20 ± 2.62
Median duration of stable disease (PASI ≤ 5) at baseline (years) 2.64 (0.00–10.38)
Number of patients that had reached PASI75 at  inclusiond 44 (71%)





 Dosing of 45 mg every 12 weeks





On first biologic treatment at baseline 30 (46%)
Previous treatment with one alternative biologic 29 (45%)
Previous treatment with two alternative biologics 2 (3%)
Previous treatment with three alternative biologics 2 (3%)
Previous treatment with four alternative biologics 2 (3%)
Co-medication
Methotrexate/Acitretin 6 (9%)
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Fig. 1  Patient needs in psoriasis 
patients with controlled disease 
sorted according to relative 
importance and subgrouped by 
biologic treatment (N = 65)
Fig. 2  Goal importance in pso-
riasis patients with controlled 
disease, sorted according to 
the percentage of patients 
that reported each individual 
treatment goal to be ‘quite 
important’ or ‘very important’ 
(N = 65)
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3.4  Personal Treatment Goals by Treatment History
At the start of the dose-reduction strategy, 30 patients were 
on their first biologic. Of the 35 patients who had previously 
used biologic therapy, 29 were being treated with their sec-
ond biologic. Classified for having had biologic treatment 
in the past, there were no significant differences in treatment 
needs between patients with a history of biologic use and 
patients on their first biologic.
3.5  Personal Treatment Goals by the Willingness 
to Participate in a Dose‑Reduction Strategy
Twenty-eight patients who did not participate in the dose-
reduction strategy volunteered to complete the PNQ. Due to 
incomplete answers, the mean importance score for seven 
PNQ items was calculated over 27 patients. Since these 
data had been collected anonymously, baseline character-
istics were unavailable. We compared this group to our 
study population. Analysed for the intent to participate in 
the dose-reduction strategy, ‘to have confidence in therapy’ 
was granted the highest mean importance score (mean PNQ 
score 3.57, 95% CI 3.18–3.96) in the group that denied dose 
reduction, with a statistically significant difference compared 
to the dose-reduction group (mean 2.97, 95% CI 2.62–3.32) 
(p = 0.02). All other treatment goals showed no significant 
differences between both groups.
4  Discussion
By means of the PNQ, our study explored personal treatment 
goals in psoriasis patients with sustained low disease activ-
ity for at least 6 months, whilst being treated with etaner-
cept, adalimumab or ustekinumab. We found that despite 
low disease activity, these patients still have substantial 
patient needs. Highest importance was attributed to goals 
on confidence in healing, which was in contrast to social 
Fig. 3  Mean importance score of treatment goals reported by psoria-
sis patients with controlled disease (N = 65), grouped according to 
each subscale of the patient needs questionnaire
Fig. 4  Difference in patient 
needs according to gender in 
a population with controlled 
psoriasis (N = 65). *p ≤ 0.05
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goals, which were valued as being of least importance. For 
female patients, it was significantly more important to ‘feel 
less depressed’ and ‘be comfortable showing yourself more 
in public’ compared to male patients. Previous treatment 
with biologic therapy was not associated with a change in 
patients’ attitude towards specific patient needs. Analysed 
for the intent to participate in a dose-reduction strategy, ‘to 
have confidence in therapy’ was granted the highest mean 
importance score in the group that denied dose reduction, 
with a significant difference compared to the dose-reduction 
group.
Treatment goals ‘to have confidence in therapy’, ‘be 
healed of all skin defects’ and ‘be free of itching’ were most 
frequently (78%) ranked as ‘quite’ to ‘very’ important. As 
stated, this cohort included patients with low disease activ-
ity only. Therefore, high importance scores could imply that 
certain treatment goals have not yet been reached in this 
population, or could express the patients’ wish that already-
achieved goals would persist. When compared to a cohort 
with high disease activity as described by Maul et al. (5343 
patients from Germany and Switzerland, mean PASI 14.2 
± 9.7, DLQI 11.3 ±7.2), ‘to get better skin quickly’ and 
‘to be healed of all skin defects’ were most important to 
patients, albeit with a higher frequency (94% ranked it as 
quite to very important). Of note, the top ten goals with 
highest importance scores were comparable in both stud-
ies. There does not seem to be a large difference between 
the relative importance of different treatment goals, based 
on ranking of PNQ items, between patients with stable low 
disease activity and patients with moderate to severe psoria-
sis. The widest variation in relative rank order was seen in 
‘to have fewer out-of-pocket-expenses’ (25th in our cohort 
vs. 16th in Maul et al.), probably due to the differences in 
healthcare-related costs [15]. To ‘be able to have a normal 
sex life’ (16th in our cohort vs. 22nd in Maul et al.) and 
‘to be able to lead a normal working life’ (19th/20th in our 
cohort vs. 25th in Maul et al.) were the only other items with 
> 5 ranks of difference between these two studies. Patients 
with higher disease activity seem to give higher importance 
scores to treatment goals compared to patients with low dis-
ease activity. The percentages of patients that reported a goal 
to be quite/very important ranged from 94.0% for the most 
important to 49.7% for the least important item in the study 
by Maul et al. In our study, however, these percentages were 
relatively lower, ranging from 78.5 to 35.4%. Nevertheless, 
even psoriasis patients with relatively low disease activity 
still have substantial patient needs, which should be consid-
ered in daily practice.
Treatment goals ‘to feel less depressed’ and ‘to be more 
comfortable showing yourself in public’ were rated signifi-
cantly more important by female compared to male patients. 
This is in line with the findings by Böhm et al., who reported 
that women perceive a greater negative impact of psoriasis 
on mental health, self-esteem and maintaining composure 
in social situations compared to men [16]. Maul et al. and 
Blome et al. found significant gender differences in patient 
needs in patients with moderate to severe psoriasis in 20, 
respectively 19, out of 25 PNQ items [7, 9]. However, since 
Fig. 5  Difference in patient 
needs according to age group 
in a population with controlled 
psoriasis (N = 65). *p ≤ 0.05
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the absolute differences in patient needs scores were rela-
tively small, these findings might be of only minor clinical 
importance. Nevertheless, it has been reported that female 
patients are less satisfied with biological treatment for pso-
riasis [17]. This study suggests that this difference may be 
independent of the current state of psoriasis, either mild or 
severe.
Patients under the age of 50 years, compared to those 
aged ≥ 50 years, reported higher mean importance scores 
in 23 out of 25 PNQ items, with significant differences in 
five items. In both our study and the study on patients with 
moderate to severe psoriasis by Blome et al. [9], ‘to be able 
to lead a normal working life’, ‘to be comfortable showing 
yourself more in public’ and ‘to have fewer side effects’ were 
rated significantly more important in patients aged < 50 
years. A history of previous treatments with biologic therapy 
was not associated with an altered attitude towards specific 
patient needs. However, most patients who had a treatment 
history with biologics had received only one other type of 
biologic. It could hypothetically be the case that more exten-
sive treatment histories would lead to differences in PNQ, 
due to negative experiences in the past.
When comparing our study population (patients moti-
vated to start dose reduction) to the patients who were eli-
gible for but denied dose reduction, we found that ‘to have 
confidence in therapy’ was of higher importance in the 
group that denied dose reduction. This could imply that lack 
of trust in their current antipsoriatic therapy played a role 
in their decision not to participate in dose reduction. This 
finding could be relevant for physicians who want to apply 
dose-reduction strategies in daily practice.
4.1  Limitations
Since this pragmatic dose-reduction strategy was part of 
daily practice, the preferred cut-off point of a PASI ≤ 5 for 
participation was not strictly enforced if patients preferred 
dose reduction over usual care. We used a PASI ≤ 5 as part 
of our definition of low disease activity, based on the prevail-
ing guidelines at the time of inclusion. Currently, treatment 
goals are shifting towards a PASI score ≤ 3 [18]. Although 
an absolute PASI ≤ 3 was not required in our study, only 
six patients had a PASI score > 3 at the start of the dose-
reduction strategy.
Since patients were asked to complete the PNQ at the start 
of a dose-tapering project, it is possible that their answers 
to the PNQ were influenced by any stress or fear of disease 
progression as a result of the new dosing strategy. However, 
since all patients volunteered and provided oral consent to 
start dose tapering, we think this effect was limited.
The PNQ is a subset of the PBI, which was originally 
designed to evaluate patient-relevant therapeutic benefits 
longitudinally, by measuring patient needs at baseline (using 
PNQ) and the extent to which these needs are achieved after 
treatment (using the PBQ, Patient Benefit Questionnaire). 
Although previously applied as such, the PNQ is not for-
mally validated for cross-sectional measurements. Since we 
did not aim to evaluate treatment benefit, we did not use the 
PBQ. However, it would have been interesting to assess to 
what extent the goals in our population had already been 
reached, or why certain patients had reported a goal to be 
‘not applicable’. This would facilitate interpretation here. 
The relatively small sample size and the fact that correc-
tion for multiple testing was not performed implies that the 
results must be interpreted with caution.
In conclusion, psoriasis patients with controlled disease 
due to biologic treatment still have substantial treatment 
goals, in an order comparable to patients with more severe 
psoriasis. They do, however, award their personal treatment 
goals a lower level of importance compared to patients with 
more severe disease described in literature. We reported 
subtle differences in patient needs stratified per gender and 
age. Clinicians who want to apply dose-reduction strate-
gies should actively inquire about the level of confidence 
in therapy, as lack of trust in their therapy may exclude eli-
gible patients from dose reduction. Since treatment goals 
differ per patient, individual treatment could be optimized 
by actively inquiring about the patient’s personal treatment 
goals. As goal importance is a distinct concept from quality-
of-life measurements, addressing both these two items could 
improve the quality of care [8].
Supplementary Information The online version contains supplemen-
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